I am a
Home I AM A Search Login

Papers of the Week

2022 Apr-Jun

ARP Rheumatol



The safety and persistence of intravenous iloprost in systemic sclerosis.


Martins P, Dourado E, Eurico Fonseca J, Romão V, Resende C
ARP Rheumatol. 2022 Apr-Jun; 1(2):122-128.
PMID: 35810370.


Vasculopathy is a crucial feature of systemic sclerosis (SSc). It occurs in almost every patient with SSc, with Raynaud's phenomenon (RP) and digital ulcers (DU) having a great impact on the quality of patients' lives. Intravenous (IV) iloprost, a synthetic analogue of prostacyclin, is broadly used to treat RP and DU secondary to SSc. Currently, there is no standard protocol defined for the iloprost treatment of SSc-associated RP and DU, and, consequently, the management of this treatment is largely based on each centre's experience.